Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
14.76
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Looking Into Takeda Pharmaceutical's Recent Short Interest
July 05, 2022
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 4.06 million shares sold short, which...
Via
Benzinga
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
July 01, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
Via
Benzinga
Moderna Pops On Updated Booster Data, But Analyst Says It Needs A 'Second Act'
June 08, 2022
Moderna tested a bivalent booster, which targets two Covid strains in one shot.
Via
Investor's Business Daily
Quant Ratings Updated on 66 Stocks
June 06, 2022
Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10.
Via
InvestorPlace
Current Report: Takeda Pharmaceutical
May 18, 2022
Takeda’s price per share was $14.31 as of yesterday's market close. One year ago its price was $17.20.
Via
Talk Markets
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
May 11, 2022
Via
Benzinga
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder
January 31, 2022
The
Via
Benzinga
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
April 22, 2022
Via
Benzinga
Novavax Stock Looks Like a Good Value With Its New Combined Vaccine
April 21, 2022
NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials.
Via
InvestorPlace
Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report
April 18, 2022
Via
Benzinga
Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference
April 13, 2022
Via
Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
April 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Monday Markets News
March 28, 2022
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved.
Via
Talk Markets
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
March 08, 2022
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID...
Via
Benzinga
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
February 22, 2022
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly...
Via
Benzinga
Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics
February 22, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four...
Via
Benzinga
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
February 18, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of...
Via
Benzinga
The Best Russell 2000 Stocks to Buy Before they Rebound
February 15, 2022
Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices.
Via
InvestorPlace
Why Are Seagen Shares Sinking Today?
February 10, 2022
Seagen Inc (NASDAQ: SGEN) reported Q4 revenues
Via
Benzinga
Take a Leap Into Novavax Stock After Vaccine Sales Start
February 08, 2022
Novavax is worth speculating on at current levels. NVAX stock has fallen below the $100 mark ahead of its global Covid-19 vaccine launch.
Via
InvestorPlace
A News Blizzard
February 04, 2022
Markets are still down despite very encouraging news in January when 467,00 new hires got jobs.
Via
Talk Markets
Worldwide Adoption of Novavax Vaccines Makes It a Winner
January 21, 2022
Novavax can still generate billions of dollars of revenue per year from its shot, making NVAX stock quite attractive at its current levels.
Via
InvestorPlace
More Serious Matters
January 14, 2022
Wall Street fell on new worries about inflation and a drop in retail sales levels.
Via
Talk Markets
Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure
January 13, 2022
Denali Therapeutics is under pressure after the FDA put its study on hold.
Via
Investor's Business Daily
Interest Rate Hikes And Stocks
January 12, 2022
Abnormal flooding in northwest Brazil has blocked iron ore mining which resulted in a jump in the price of ore.
Via
Talk Markets
Post-Fed Thursday
January 06, 2022
Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today.
Via
Talk Markets
FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study
December 22, 2021
Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral...
Via
Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
December 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With...
Via
Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
December 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...
Via
Benzinga
Novavax Files For Approval Of Its COVID-19 Vaccine In Japan
December 16, 2021
Novavax Inc (NASDAQ: NVAX) has submitted a marketing application in Japan seeking approval for its COVID-19 vaccine by its partner Takeda Pharmaceutical Co Ltd...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.